Papers: 4 Apr 2014 - 11 Apr 2014
Clinical experience of natalizumab in Crohn's disease patients in a restricted distribution program.
Intermediate uveitis in children and young adults: differences in clinical course, associations and visual outcome.
The Relationship Between Familial Mediterranean Fever Gene (MEFV) Mutations and Clinical and Radiological Parameters in Multiple Sclerosis Patients.
Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis.
Features of anti-aquaporin 4 antibody-seronegative Thai patients with neuromyelitis optica spectrum disorders: A comparison with seropositive cases.
In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand 11C-PK11195.
Telephone counseling and home telehealth monitoring to improve medication adherence: Results of a pilot trial among individuals with multiple sclerosis.
The synthetic retinoid Am80 delays recovery in a model of multiple sclerosis by modulating myeloid-derived suppressor cell fate and viability.
Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales.
Brain activity changes in cognitive networks in relapsing-remitting multiple sclerosis - insights from a longitudinal FMRI study.
Interactions and tradeoffs between cell recruitment, proliferation, and differentiation affect CNS regeneration.
A longitudinal study on fatigue, depression, and their relation to neurocognition in multiple sclerosis.
Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices.
Accuracy of StepWatch™ and ActiGraph Accelerometers for Measuring Steps Taken among Persons with Multiple Sclerosis.
Immunomodulatory effects of adipose-derived mesenchymal stem cells on the gene expression of major transcription factors in T cell subsets.
Modulation of alertness by sustained cognitive demand in MS as surrogate measure of fatigue and fatigability.
Bilateral Surgical Reconstruction for Internal Jugular Veins Disease in Patients With Chronic Cerebrospinal Venous Insufficiency and associated Multiple Sclerosis.
BENEFIT 8-year results provide further support for the long-term value of early treatment of multiple sclerosis.
Internet-delivered lifestyle physical activity intervention improves body composition in multiple sclerosis: Preliminary evidence from a randomized controlled trial.
The detection of THC, CBD and CBN in the oral fluid of Sativex(®) patients using two on-site screening tests and LC-MS/MS.
Isolated anti-β2-glycoprotein I antibodies in neurology: a frontier syndrome between multiple sclerosis and antiphospholipid syndrome?
Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions.
Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59.
Effects of Gadolinium Contrast Agent Administration on Automatic Brain Tissue Classification of Patients with Multiple Sclerosis.
Does fatigue occur in MS patients without disability? Suggested running head: Fatigue and disability in MS.
Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment.
Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation.
Correction: Combined Acquisition Technique (CAT) for Neuroimaging of Multiple Sclerosis at Low Specific Absorption Rates (SAR).
The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis.
A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome.
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis.
Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis.